When to Convert from Short-Acting to Long-Acting Opioids in Chronic Non-Cancer Pain
Convert to long-acting opioids only when chronic pain is controlled on stable doses of short-acting opioids taken consistently around-the-clock, typically requiring multiple daily doses. This conversion should never be the initial approach to opioid therapy.
Initial Opioid Therapy: Always Start Short-Acting
Start all patients with immediate-release (short-acting) opioids, never with extended-release/long-acting (ER/LA) formulations 1, 2. This applies to acute, subacute, and chronic pain. The 2022 CDC guidelines explicitly state that ER/LA opioids should not be used to initiate opioid treatment for chronic pain 2.
Key Principle
Long-acting opioids are reserved for severe, continuous pain and should only be considered after establishing opioid tolerance and stable dosing with immediate-release formulations 2.
Specific Criteria for Conversion
Convert to long-acting opioids when ALL of the following conditions are met:
1. Pain Pattern Requirements
- Continuous, persistent pain (not intermittent)
- Pain present throughout most of the day requiring regular dosing 3
- Not for "as-needed" or breakthrough pain only 2
2. Dosing Stability Achieved
- Patient has been on stable doses of short-acting opioids
- Consistent around-the-clock administration established 3
- Pain adequately controlled at current short-acting dose
- FDA guidance suggests at least 1 week of consistent immediate-release opioid use at certain dosages before considering ER/LA conversion 2
3. Functional Goals Met
- Patient demonstrates acceptable comfort and function on current regimen 4
- 24-hour opioid requirement is stable and predictable 3
The Conversion Process
Step-by-Step Algorithm:
Calculate total 24-hour opioid dose from all short-acting opioid sources taken in the previous day 3
Determine equianalgesic dose of the chosen long-acting formulation using conversion tables
Reduce the calculated dose by 25-50% to account for incomplete cross-tolerance between formulations 3
Divide the total daily dose appropriately:
- Every 12 hours for most extended-release oral formulations
- Every 72 hours for transdermal fentanyl patches 3
Prescribe breakthrough medication: Provide short-acting opioids at 10-20% of the total 24-hour dose for rescue/breakthrough pain 3
Critical Caveats and Pitfalls
What NOT to Do:
- Never initiate opioid therapy with ER/LA formulations 1, 2
- Never prescribe ER/LA opioids for intermittent or as-needed use 2
- Avoid methadone as first-choice ER/LA opioid due to complex pharmacokinetics, QT prolongation risk, and need for specialized monitoring 1, 2
- Exercise extreme caution with transdermal fentanyl - only prescribe if thoroughly familiar with its unique dosing and absorption properties 1, 2
Special Populations Requiring Extra Caution:
- Renal or hepatic dysfunction: Consider longer dosing intervals due to decreased drug clearance and risk of toxic accumulation 2
- Older adults: Assess for cognitive limitations that might interfere with medication management 1
Ongoing Management After Conversion
Monitoring Requirements:
- Continue short-acting opioids for breakthrough pain (same opioid when possible) 3
- If patient persistently needs rescue doses, increase the ER/LA dose accordingly 3
- Reassess at each contact to ensure treatment goals for comfort and function are met 4
Dose Escalation Triggers:
Increase ER/LA dose when:
- Patient consistently requires multiple breakthrough doses daily
- Pain relief inadequate at peak effect of ER/LA medication
- Pain returns at end of dosing interval 3
Context: Chronic Non-Cancer Pain Specifics
While the provided evidence primarily addresses cancer pain [3-4,3-3], the principles apply to chronic non-cancer pain with additional restrictions. The 2022 CDC guidelines emphasize that for chronic non-cancer pain, the threshold for using ER/LA opioids should be even higher, with careful justification required 2. The emergency medicine guideline explicitly states that long-acting opioids are indicated for chronic pain management, not acute pain, and should never be used in emergency settings for new-onset pain 5.
The fundamental principle remains: establish efficacy and stable dosing with immediate-release opioids first, then convert to long-acting formulations only for continuous pain requiring around-the-clock coverage.